May 2026
M	T	W	T	F	S	S
	1	2	3
4	5	6	7	8	9	10
11	12	13	14	15	16	17
18	19	20	21	22	23	24
25	26	27	28	29	30	31

Heghine Khachatryan: The Emerging Era of Immunothrombosis and Precision Vascular Medicine

Heghine Khachatryan/LinkedIn

May 11, 2026, 01:38

Heghine Khachatryan: The Emerging Era of Immunothrombosis and Precision Vascular Medicine

Heghine Khachatryan, Editor-in-Chief of Hemostasis Today, Head of Hemophilia and Thrombosis Center at Yeolyan Hematology and Oncology Center, shared RPTH’s post on LinkedIn:

“An outstanding and conceptually rich review highlighting how modern platelet biology has moved far beyond the classical ‘hemostasis-only’ paradigm.

What is particularly compelling is the emerging view of platelets as dynamic immune-effector cells that actively orchestrate thromboinflammation, vascular surveillance, innate immunity, and tissue signaling.

The idea that platelet phenotypes are context-dependent rather than simply ‘activated’ or ‘resting’ reflects a major shift in contemporary hematology and vascular biology.

Especially important are the implications for:

immunothrombosis and NETosis,
cancer-associated thrombosis,
sepsis and endothelial dysfunction,
autoimmune and inflammatory diseases,
and precision antithrombotic therapy.

The discussion around platelet heterogeneity and modular effector programs may ultimately reshape how we classify thrombotic and inflammatory disorders in the coming years.

Selective targeting of pathogenic thromboinflammatory pathways while preserving physiologic vascular protection remains one of the most important unresolved challenges in the field.

A highly valuable contribution for clinicians and researchers working across hemostasis, thrombosis, vascular medicine, immunology, and translational hematology.”

RPTH journal shared a post on LinkedIn about recent article by Raphael Escaig et al., adding:

“Are platelets really just clotting cells or immune orchestrators?

We’ve long viewed platelets through a hemostasis lens.

But emerging data are reshaping that paradigm.

A new State-of-the-Art review in RPTH breaks this wide open.

Here’s the key signal:

Platelets actively coordinate innate and adaptive immunity
Distinct effector programs (procoagulant, secretory, immune-interacting) operate in parallel
These functions are context-dependent, protective vs pathogenic

What’s changing under the hood:

Platelets migrate (Arp2/3-driven haptotaxis) to sites of injury and infection
Procoagulant platelets localize coagulation to microlesions (not just thrombi)
Platelet-neutrophil interactions drive NETosis and thromboinflammation
Platelet aging shifts function – hemostatic – immune

Conceptual insight:

Platelets are not ‘activated vs resting’
They operate as modular effector systems tuned by the microenvironment

Big questions for the field:

What dictates which platelet program dominates in disease?
Can we selectively block thromboinflammation without impairing vascular protection?
How does platelet programming (e.g., megakaryocyte origin, cargo) shape outcomes?
Platelet biology is evolving, and it’s becoming clear that thrombosis, inflammation, and immunity are deeply intertwined.”

Title: Platelet effector functions in inflammation

Authors: Raphael Escaig, Lennart Kreutz, Rainer Kaiser, Leo Nicolai